Central Nervous System Biomarkers Market Size, Share & Industry Analysis, By Biomarker Type (Molecular Biomarkers, Imaging Biomarkers, Electrophysiological & Physiological Biomarkers, and Others), By Application (Disease Diagnosis, Drug Discovery & Development, Disease Risk Assessment, and Others), By Disease Indication (Alzheimer Disease, Parkinson’s Disease, Multiple Sclerosis, Traumatic Brain Injury, and Others), By End User (Hospitals & Clinics, Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, and Others), and Regional Forecast, 2026-2034

The global central nervous system biomarkers market size was valued at USD 7.25 billion in 2025 and is projected to grow from USD 8.10 billion in 2026 to USD 18.20 billion by 2034, exhibiting a CAGR of 10.6% during the forecast period.

Central Nervous System (CNS) biomarkers are measurable biological indicators of normal bodily functions, disease processes, or responses to medical treatments involving the brain and spinal cord. The increasing prevalence of neurological conditions, surging demand for blood-based CNS biomarker testing, technological advancements, growing geriatric population, and increasing healthcare expenditure are driving market expansion.

• For instance, according to the 2025 data published by the Alzheimer’s Association, approximately 7.2 million Americans aged 65 and older are living with Alzheimer's in the U.S.

Key players such as F. Hoffmann-La Roche Ltd. and QIAGEN emphasize product innovation to maintain their dominance.

Central Nervous System Biomarkers Market Trends

Shift from Cerebrospinal Fluid (CSF) Toward Blood-Based CNS Biomarkers

There is an increasing shift from Cerebrospinal Fluid (CSF) analysis and positron Emission Tomography (PET) toward blood-based CNS biomarkers globally. Advancements in highly sensitive plasma assays, especially p-tau217, p-tau231, p-tau181, GFAP, Aβ42/Aβ40, and neurofilament light chain (NfL), are increasingly allowing CNS-related pathological changes to be detected through routine blood samples. Along with this, there is an increasing focus by regulatory authorities to promote the use of blood-based biomarkers, fueling product demand.

• In July 2025, the Alzheimer’s Association issued its first clinical practice guideline for blood-based biomarkers. It stated that sufficiently accurate blood tests can potentially substitute for amyloid PET or CSF biomarker testing in specialized-care patients with cognitive impairment.

Market Dynamics

Market Drivers

Download Free sample to learn more about this report.

Increasing Prevalence of Neurological Conditions is Fueling Market Growth

The growing prevalence of chronic conditions, including Parkinson’s disease, multiple sclerosis, and others, is boosting adoption of central nervous system biomarkers for detection, diagnosis, and monitoring among healthcare professionals.

• For instance, according to 2026 data published by the Parkinson’s Foundation, approximately 1.1 million people are affected by Parkinson’s disease in the U.S.

Increased investments in neuroscience research and brain health initiatives and surging focus of key companies on developing novel biomarkers are bolstering the global central nervous system biomarkers market growth.

Market Restraints

High Costs of Central Nervous System Biomarkers Hinder Market Growth

High costs associated with central nervous system biomarkers remain a major limitation in the market. The established biomarker-confirmation methods, including amyloid PET, tau PET, and cerebrospinal fluid (CSF) testing, require advanced infrastructure, qualified professionals, advanced laboratory or imaging devices, and, in the case of PET, costly radiopharmaceuticals. These requirements significantly increase the cost per diagnostic test, further restricting widespread adoption in major hospitals, academic medical centers, and specialized neurology clinics.

• For instance, according to the 2023 data published by the Canadian Medical Imaging Inventory, the estimated procurement and construction costs for a PET-CT unit are around USD 7.2 million.

Market Opportunities

Ongoing Healthcare Infrastructure Investments to Create Significant Growth Opportunities

There is an ongoing expansion of healthcare infrastructure in emerging countries, creating opportunities for the market. Government organizations are also focusing on strengthening laboratory networks and tertiary healthcare. Expanded diagnostic laboratories are supporting testing for biomarkers, including amyloid-beta, p-tau217, NfL, GFAP, and α-synuclein, and increasing the availability of tertiary hospitals and specialist physicians is further increasing testing among patients with Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, traumatic brain injury, and other neurological conditions. These investments, along with growing healthcare expenditure, are boosting access to detection, diagnosis, and monitoring of chronic conditions among patients, thereby driving the adoption rate of central nervous system biomarkers, including molecular biomarkers, imaging biomarkers, and others.

• According to PM–Ayushman Bharat Health Infrastructure Mission (PM-ABHIM), 744 integrated public health laboratories, 621 critical care blocks, and 2,151 block public health units have been approved for establishment/construction or upgrading in India.

Market Challenges

Limited Healthcare Access in Developing Countries to Limit Market Growth

The limited access to advanced healthcare infrastructure in many developing countries remains a key challenge for the market. Limited neurology professionals, specialty clinics, and diagnostic capabilities in emerging countries, including Brazil and Mexico are hampering the demand for advanced central nervous system biomarkers.

Limited per capita healthcare expenditure, inadequate insurance frameworks, and disparities in urban–rural healthcare access facilities are limiting the adoption of these advanced technologies. Therefore, despite the growing prevalence of neurological conditions, many patients in emerging nations are unable to access advanced care, thereby hindering market growth.

• For instance, according to 2023 data published by The World Bank Group (WBG), approximately 4.5 billion people lack full access to essential health services globally.

SEGMENTATION ANALYSIS

By Biomarker Type

Molecular Biomarkers Led Market Due to Rise in Diagnostic Procedures for Various Neurological Conditions

Based on the biomarker type, the market is classified into molecular biomarkers, imaging biomarkers, electrophysiological & physiological biomarkers, and others.

The molecular biomarkers segment held the largest revenue share in 2025, owing to the growing number of diagnostic procedures for various neurological conditions among the patient population globally. This, along with the increasing focus of key players on introducing innovative products, contributes to segment growth.

• For instance, in May 2025, the FDA evaluated the Lumipulse pTau217/β-Amyloid plasma test using 499 cognitively impaired adults. Among positive blood-test results, 91.7% were confirmed amyloid-positive by PET or CSF, while 97.3% of negative blood-test results corresponded with negative PET or CSF findings.

The electrophysiological & physiological biomarkers segment is expected to grow at a CAGR of 8.6% over the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Application

Growing Emphasis on Early Disease Detection Led to Disease Diagnosis Segment Dominance

Based on application, the market is segmented into disease diagnosis, drug discovery & development, disease risk assessment, and others.

The disease diagnosis segment dominated the global market with a share of 47.5% in 2025. The growing emphasis on early disease detection, increasing use of biomarkers for differential diagnosis and disease monitoring, and advancements in biomarker discovery and validation are supporting segment growth. The rising number of neurological diagnostic procedures and increasing adoption of multiple sclerosis biomarkers in clinical and research settings are further contributing to the segment’s expansion.

For instance, according to data published by the World Health Organization (WHO) in 2023, about 1.8 million people have multiple sclerosis globally.

The drug discovery & development segment is set to grow at a CAGR of 9.9% over the forecast period.

By Disease Indication

Growing Prevalence of Alzheimer's Disease Led to Segment Dominance

Based on disease indication, the market is segmented into Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, traumatic brain injury, and others.

The Alzheimer’s disease segment dominated the global market with a share of 33.6% in 2025. The segment growth is driven by the high and growing prevalence of Alzheimer’s disease, the increasing geriatric population, and rising demand for effective treatment options.

• For instance, according to the 2026 data published by the Alzheimer’s Association, it was reported that more than 1.5 million people are living with Alzheimer’s disease in Germany.

The traumatic brain injury segment is set to grow at a CAGR of 9.4% over the forecast period.

By End User

Hospitals & Clinics Led Market Due to Growing Adoption of Advanced CNS Biomarkers

Based on end user, the market is divided into hospitals & clinics, diagnostic laboratories, pharmaceutical & biotechnology companies, and others.

The hospitals & clinics segment dominated the central nervous system biomarkers market share in 2025. The increasing number of diagnostic procedures and growing adoption of advanced CNS biomarkers, including cerebrospinal fluid biomarkers, in hospitals are contributing to segment growth. Furthermore, the segment is set to hold a 41.0% share in 2026.

• For instance, according to 2025 data published by Statistisches Bundesamt, there are about 1,874 hospitals in Germany.

Pharmaceutical & biotechnology companies are projected to grow at a 10.6% CAGR during the forecast period.

Central Nervous System Biomarkers Market Regional Outlook

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America held the dominant market share in 2024, valued at USD 2.60 billion, and also took the leading share in 2025 with USD 2.91 billion. The growing disease burden of neurological conditions, advanced healthcare infrastructure, and the development of central nervous system biomarkers are driving market growth in the region.

• For instance, in August 2025, Labcorp, a global company of innovative and comprehensive laboratory services, announced the availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio, the first blood-based in vitro diagnostic (IVD) test cleared by the U.S. Food and Drug Administration (FDA) to aid in the diagnosis of Alzheimer's disease through early detection of the amyloid plaques associated with the disease in appropriate patients.

U.S. Central Nervous System Biomarkers Market

Based on North America’s strong contribution and the U.S. dominance within the region, the U.S. market can be analytically approximated at around USD 2.90 billion in 2026, accounting for roughly 35.8% of global sales.

Europe

Europe is projected to record a CAGR of 9.3% in the coming years, which is the second highest among all regions, and reach a valuation of USD 2.14 billion in 2026. The strong presence of neuroscience research institutes and increasing adoption of neurodiagnostics is supporting market growth.

U.K. Central Nervous System Biomarkers Market

The U.K. market in 2026 is estimated at around USD 0.37 billion, representing roughly 4.5% of global revenues.

Germany Central Nervous System Biomarkers Market

The German market is projected to reach approximately USD 0.42 billion in 2026, equivalent to around 5.1% of global sales.

Asia Pacific

Asia Pacific is estimated to reach USD 2.06 billion in 2026 and secure the position of the third-largest region in the market. Market growth is driven by expanding healthcare systems and growing adoption of neurodegenerative disease biomarkers.

Japan Central Nervous System Biomarkers Market

The Japanese market in 2026 is estimated at around USD 0.53 billion, accounting for roughly 13.0% of global revenues.

China Central Nervous System Biomarkers Market

The market in China is projected to be one of the largest globally, with 2026 revenues estimated at around USD 0.66 billion, representing roughly 8.2% of global sales.

India Central Nervous System Biomarkers Market

The Indian market size in 2026 is estimated at around USD 0.29 billion, accounting for roughly 3.5% of global revenues.

Latin America and Middle East & Africa

The Latin America and Middle East & Africa regions are expected to witness moderate growth in this market space during the forecast period. The Latin America market is set to reach a valuation of USD 0.39 billion in 2026.  The growth is due to the increasing demand for precision neurology and CNS drug development among the key companies in the region. Market growth in the Middle East & Africa is driven by increasing adoption of CNS biomarkers, including neurological biomarkers, Parkinson’s disease biomarkers, and traumatic brain injury biomarkers in the region. In the Middle East & Africa, the GCC is set to reach a value of USD 0.13 billion in 2026.

South Africa Central Nervous System Biomarkers Market

The market in South Africa is projected to reach around USD 0.05 billion in 2026, representing roughly 0.7% of global revenues.

Competitive Landscape

Key Industry Players

Increasing Number of Product Approvals to Support Key Players’ Dominance

• Hoffmann-La Roche Ltd. and QIAGEN are the leading companies in the central nervous system biomarkers market. A diversified product portfolio, along with a strong focus on inorganic growth strategies globally, is one of the key factors contributing to their dominance. Furthermore, the growing focus of key companies on receiving product approvals is expected to strengthen their presence in the coming years.
• For instance, in October 2025, Hoffmann-La Roche Ltd. received approval for the Elecsys pTau181 test, a blood-based biomarker (BBM) test indicated as an aid in the initial assessment for Alzheimer’s disease and other causes of cognitive decline in the primary-care setting.
• Other key players, including Thermo Fisher Scientific Inc. and Beckman Coulter, Inc., focus on product launches and acquisitions to strengthen their market presence.

List of Key Central Nervous System Biomarkers Companies Profiled

• Hoffmann-La Roche Ltd. (Switzerland)
• Thermo Fisher Scientific Inc. (U.S.)
• QIAGEN (Netherlands)
• Fujirebio (Japan)
• GE Healthcare (U.S.)
• Labcorp (U.S.)
• Quest Diagnostics (U.S.)
• Beckman Coulter, Inc. (U.S.)
• Siemens Healthineers AG (Germany)
• Bio-Techne (U.S.)

KEY INDUSTRY DEVELOPMENTS

• August 2026: C2N Diagnostics received FDA clearance for its PrecivityAD2® test, a blood-based test designed to aid healthcare professionals in assessing Alzheimer's disease pathology in conjunction with standard clinical evaluation.
• April 2026: Sysmex Corporation launched “HISCL p-Tau217 Assay Kit for Research Use”, a reagent for research purposes to identify a biomarker1 related to Alzheimer's disease, namely blood p-Tau2172 levels, in Europe.
• March 2026: Siemens Healthineers AG expanded brain health research offerings, with the brain-derived, fully automated Atellica IM Phosphorylated tau 217 (pTau217) and Atellica IM Brain Derived Tau (BDTau) assays for brain health research.
• March 2022: Fujirebio announced the availability of the Lumipulse G pTau 181 Plasma assay for the fully automated LUMIPULSE G immunoassay systems with an aim to increase its brand presence.
• March 2022: Quanterix Corporation, a company digitizing biomarker analysis to advance the science of precision health, collaborated with Eli Lilly and Company to advance the diagnosis, monitoring, and treatment of Alzheimer’s disease.

REPORT COVERAGE

The report provides a detailed global central nervous system biomarkers market analysis and focuses on key aspects such as leading companies and market segmentation, including biomarker type, application, disease indication, and end user. Besides this, the global report offers insights into the market growth trends and highlights key industry developments. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth of the market over recent years.

Request for Customization   to gain extensive market insights.

Report Scope and Segmentation

Research Methodology

1. Bottom-Up Approaches

Approach 1: Revenues and Market Share of Major CNS Biomarker Players

• Collect CNS-biomarker-specific or attributable revenue evidence from annual reports, SEC filings, investor presentations, earnings materials, regulatory disclosures, and product portfolios.
• Map the 15 profiled companies plus other specialized players across molecular, imaging, physiological/electrophysiological and other biomarker modalities.
• Estimate only in-scope revenue attributable to CNS assays, reagents, specialized testing, radiodiagnostics and biomarker analytics; exclude generic analyzer/scanner revenue and therapeutic sales.
• Adjust manufacturer, laboratory, licensing, royalty and partner revenues to avoid double counting when the same test is represented at multiple points in the value chain.
• Triangulate company-derived revenue with product availability, geographic commercialization, regulatory status and test/adoption indicators.

Approach 2:    Product/Test-Level Sales and Utilization Analysis

• Identify commercial CNS biomarker products and services: automated immunoassays, RUO kits, mass-spectrometry tests, PET tracers, proteomic panels and specialist laboratory testing.
• Estimate annual test volumes, reagent pull-through, panel utilization, radiotracer doses, service volumes and applicable manufacturer/test-provider ASPs by country and end user.
• Use actual commercialization milestones and laboratory volumes to constrain assumptions, particularly for recently launched blood-based Alzheimer tests.
• Allocate revenue by biomarker type, application, disease indication and end user based on the primary paid use case, with a single revenue instance assigned within each dimension.
• Sum country/product estimates and compare with company-attributable revenue to identify over- or under-estimation.

Approach 3:    Epidemiology and Eligible-Patient / Addressable-Demand Model

• Estimate diagnosed and addressable populations for Alzheimer disease, Parkinson disease, multiple sclerosis, traumatic brain injury and other CNS indications by country.
• Apply biomarker-testing eligibility, clinical-setting access, specialist referral, treatment-selection requirements, trial participation and repeat-testing assumptions.
• Differentiate established-market clinical penetration from research/trial demand and from emerging-market access limitations.
• Apply modality-specific utilization: blood/CSF testing, molecular imaging, physiological/electrophysiological assessment and other in-scope biomarker solutions.
• Multiply eligible testing episodes by net provider/manufacturer revenue per test or episode and aggregate to regional/global totals.

2. Top Down Approaches

Approach 1: Analysis of Parent CNS Diagnostics, Neurodiagnostic Testing, and Precision-Neurology Market

• Analysis of total national healthcare expenditure, diagnostic-testing expenditure, neurological care expenditure, and neuroscience-related diagnostic spending as the primary addressable expenditure pool for the Central Nervous System Biomarkers Market.
• Identification of the proportion of neurological/CNS diagnostic expenditure attributable specifically to biomarker-based diagnosis, disease-risk assessment, disease monitoring, treatment-response assessment, and drug discovery & development.
• Exclusion of non-biomarker expenditure including conventional neurological consultations, therapeutic drug revenues, hospital service revenues, generic laboratory testing, routine imaging procedures, and general-purpose diagnostic equipment.
• Estimation of CNS-biomarker-addressable expenditure associated with Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, traumatic brain injury, and other CNS disorders, based on disease burden, diagnosed populations, and clinical-testing intensity.
• Application of country-specific CNS biomarker penetration rates based on availability and utilization of molecular assays, imaging biomarkers, electrophysiological & physiological biomarkers, and other emerging biomarker modalities.
• Adjustment for differences in blood-based biomarker adoption, CSF testing utilization, PET/MRI biomarker use, specialized laboratory access, clinical-trial activity, and biomarker-guided treatment pathways across countries.
• Assessment of expenditure attributable to pharmaceutical and biotechnology R&D, including CNS clinical trials using biomarkers for patient stratification, target engagement, treatment-response monitoring, safety assessment, and endpoint development.
• Adjustment for differences in reimbursement, payer coverage, regulatory approvals, diagnostic guidelines, laboratory infrastructure, specialist availability, and healthcare-system maturity across developed and emerging markets.
• Application of country-specific ratios to convert the broader CNS diagnostic and research expenditure pool into commercial CNS biomarker revenues at manufacturer/developer/test-provider level, while excluding distributor markups and preventing double counting of assay and testing-service revenues.
• Comparison of CNS biomarker expenditure as a proportion of total neurological diagnostic and research spending across comparable countries to identify outliers and calibrate markets with incomplete primary data.
• Aggregation of country-level top-down estimates to derive regional and global Central Nervous System Biomarkers Market values.
• Comparison of the final top-down estimate with company-level CNS biomarker revenues, biomarker test-volume × ASP models, disease-population models, drug-development utilization models, and regional/country bottom-up estimates before finalizing the global market size.

3. List of Key Sources

• Annual reports, SEC filings, investor presentations, earnings releases and product-specific company disclosures.
• U.S. FDA approval/clearance, recall and Biomarker Qualification resources; European Commission IVDR resources; PMDA, NMPA, CDSCO and TGA regulatory sources.
• WHO neurological-burden evidence; OECD health-system/diagnostic technology statistics; World Bank health-spending indicators.
• NINDS and NIA biomarker-development, clinical-trial and neurodegeneration research resources.
• National health ministries, disease registries, clinical guidelines and reimbursement/coverage decisions.
• Peer-reviewed clinical validation evidence is used where needed for performance assumptions, but product-market revenue remains anchored to commercial sources.

4. Primary Interviews

Supply Side Interviews: 60%

• Key Respondents:
• CNS biomarker assay manufacturers and developers; diagnostic-platform product leaders.
• Specialty/reference laboratory executives and clinical-test commercialization teams.
• Radiopharmaceutical / molecular-imaging commercial and operations leaders.
• Biomarker discovery, proteomics and translational-research providers.
• Regulatory affairs, market access, reimbursement and quality-management professionals.
• Distributors, laboratory network managers and clinical-trial central-lab executives
• Demand Side Interviews: 40%
• Key respondents:
• Neurologists, memory-clinic physicians, neuro-oncologists and neurocritical-care specialists.
• Clinical pathologists, laboratory directors and molecular diagnostics leaders.
• Pharmaceutical/biotechnology biomarker leads, translational-medicine teams and clinical-trial scientists.
• Payers, HTA experts and reimbursement specialists.
• Academic neuroscience investigators and biobank/consortium leaders.
• Hospital procurement, laboratory operations and precision-medicine program managers.